New Strategy for the Treatment of Advanced or Recurrent Gastric Carcinoma: Neoadjuvant Immunochemotherapy of FLPO Regimen (5-FU, Leucovorin, CDDP, and OK-432)

  • Takaki Yoshikawa
  • Hisahiko Motohashi
  • Akira Tsuburaya
  • Osamu Kobayashi
  • Motonori Sairenji
  • Yoshikazu Noguchi


Gastric carcinoma is a leading cause of cancer death in Japan. Although mortality has gradually decreased, reflecting more early-staged disease, the prognosis of patients with advanced or recurrent gastric cancer remains poor. Surgical resection is considered a treatment of choice, but surgery alone has not produced significant improvement in survival of those with advanced disease.


Gastric Cancer Clin Oncol Gastric Carcinoma Gastric Cancer Patient Advanced Gastric Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke A, Meyer J, Bunte H (1988) Chemotherapy of gastric cancer. Cancer Treat Rev 15: 257–277PubMedCrossRefGoogle Scholar
  2. 2.
    Wilke H, Preusser P, Fink U, Achterrath W, Meyer H-J, Stahl M, Lenaz L, Meyer J, Siewert JR, Geerlings H, Kohne-Wompner CH, Harstrick A, Schmoll HJ (1990) New development in the treatment of gastric carcinoma. Cancer Treat Rev 17: 61–70Google Scholar
  3. 3.
    Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer J-H, Bunte H (1989) Phase II study with combination of etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310–1317PubMedGoogle Scholar
  4. 4.
    Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliverira J, Bognel C, Lasser P, Ychou M, Elias D, Cvitkovic E, Armand JP, Droz JP (1994) Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric Carcinoma: a phase II trial with prognostic factor analysis. Eur J Cancer 30A:1263–1269PubMedCrossRefGoogle Scholar
  5. 5.
    Kelson D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10:541–548Google Scholar
  6. 6.
    Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF, for the North Central Cancer Treatment Group (1994) Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 12:412–416PubMedGoogle Scholar
  7. 7.
    Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813–3818PubMedCrossRefGoogle Scholar
  8. 8.
    Carter SK (1974) Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev 1:1–13PubMedCrossRefGoogle Scholar
  9. 9.
    Nakajima T, Ota K, Ishihara S, Oyama S, Nishi M, Ohashi Y, Yanagisawa A (1997) Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 4:203–208PubMedCrossRefGoogle Scholar
  10. 10.
    Crooker P, Leichman CG, Leichman L, Tan M, Laine L, Stain S, Baranda J, Casagrande Y, Groshen S, Silberman H (1997) Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer 79:1767–1775CrossRefGoogle Scholar
  11. 11.
    Nashimoto A, Sasaki J, Tanaka O, Tsutsui M, Tsuchiya Y, Makino H (1998) Neoadjuvant chemotherapy for advanced gastric carcinoma with non-curative clinical factors. Nippon Shokaki Geka Gakkai Zassi (Jpn J Gastroenterol) 31:2199–2205CrossRefGoogle Scholar
  12. 12.
    Leichman L, Silberman H, Leichman CG, Spears CP, Ray M, Muggia FM, Kiyabu M, Radin R, Laine L, Stain S, Fuerst M, Groshen S, Donovan A (1992) Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol 10:1933–1942PubMedGoogle Scholar
  13. 13.
    Okugawa T, Onodera S, Rino Y, Okada K, Kobayashi O, Sairenji M, Motohashi H (1994) A combination chemotherapy of 5-fluorouracil, leucovorin, and cisplatin (FLP therapy) for advanced and reccurent gastric cancer. Nippon Gekakei Rengo Gakkai Zassi (Jpn Coll Surg) 19:47–51Google Scholar
  14. 14.
    Lokich JJ, Ahlgren JD, Gullo J, Phillips JA, Fryer JG (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7:167–172Google Scholar
  15. 15.
    Japanese Research Society for Gastric Cancer Association (1995) Japanese classification of gastric carcinoma, first English edition. Kanehara, TokyoGoogle Scholar
  16. 16.
    Moynihan T, Hansen R, Anderson T, Quebbeman E, Beatty P, Ausman R, Ritch P, Chitambar C, Vukelich M (1988) Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 11:461–464PubMedCrossRefGoogle Scholar
  17. 17.
    Kish JA, Ensley JF, Jacobs J, Weaver A, Cummings G, Alsarraf M (1985) A randomized trial of cisplatin + 5-FU infusion and cisplatin + 5-FU bolus for recurrent and advanced squamous cell carcinoma of head and neck. Cancer 56:2740–2744PubMedCrossRefGoogle Scholar
  18. 18.
    Hansen RM, Ryan L, Anderson T, Krzywda B, Quebbeman E, Benson A (1996) Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88:668–674PubMedCrossRefGoogle Scholar
  19. 19.
    Blijham G, Bleiberg H, Duez N, Buyse M (1990) An EORTC phase II study of sequential methotrexate fluorouracil in locally advanced or metastatic gastric cancer. Eur J Cancer 26:63–65PubMedCrossRefGoogle Scholar
  20. 20.
    Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquest J, Vandenblucke JM, Misset JL, Schwarzenberg L, Fourtillan JB, Gaget H, Mathe G (1986) Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4:685–696PubMedGoogle Scholar
  21. 21.
    Berenberg JL, Tangen C, Macdonald JS, Oishi N, Guy JT, Fleming TR (1995) Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer: a Southwest Oncology Study Group. Cancer 76:715–719PubMedCrossRefGoogle Scholar
  22. 22.
    Pratesi G, Gianni L, Manzotti C, Zunino F (1988) Sequential dependence of the antitumor and toxic effects of 5-FU and cisplatin combination on primary colon tumor in mice. Cancer Chemother Pharmacol 21:237–240PubMedCrossRefGoogle Scholar
  23. 23.
    LoRusso P, Pazdur R, Redman BG, Kinzie J, Vaitkevicius (1989) Low-dose continuous infusion of 5-fluorouracil and cisplatin: phase II study evaluation in advanced colorectal carcinoma. Am J Clin Oncol 12:486–490PubMedCrossRefGoogle Scholar
  24. 24.
    Cantrell JE, Hart RD, Taylor RF, Harvey JH Jr (1987) Pilot trial of continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer. Cancer Treat Rep 71: 615–618PubMedGoogle Scholar
  25. 25.
    Schabel FM, Trader MW, Laster WR, Corbett TH, Griswold DP Jr (1979) Cis-dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459–1473PubMedGoogle Scholar
  26. 26.
    Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, AI-Sarraf M (1985) Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 55:1123–1128PubMedCrossRefGoogle Scholar
  27. 27.
    Chung YS, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, Maeda K, Sawada T, Kato Y, Shirasaka T, Sowa M (1997) Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 80:1–7PubMedCrossRefGoogle Scholar
  28. 28.
    Ishii Y, Yamaoka H, Toh K, Kikuchi K (1976) Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432. Jpn J Cancer Res 67:115–119Google Scholar
  29. 29.
    Uchida A, Hoshino T (1980) Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer 45:476–483PubMedCrossRefGoogle Scholar
  30. 30.
    Maehara Y, Okuyama T, Kakeji Y, Baba H, Furukawa M, Sugimachi K (1994) Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 168:36–40PubMedCrossRefGoogle Scholar
  31. 31.
    Kim JP, Kwon OJ, Oh ST, Yang HK (1992) Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 216:269–278PubMedCrossRefGoogle Scholar
  32. 32.
    Yanagawa E, Toge T, Yamaguchi Y, Kuninobu H, Kuroi K, Kegoya Y, Baba N, Takayama T, Sato Y (1991) Effects of the oral and intratumoral administration of OK-432 on the immuno-reactivities of regional lymph nodes in gastric cancer patients. Jpn J Surg 21:297–303PubMedCrossRefGoogle Scholar
  33. 33.
    Motohashi H, Tsuburaya A (1996) Treatment strategy for schirrhous gastric carcinoma chracterized by the analysis of the long-term survivors. Shokaki Geka (Gastroenterol Surg) 19:1425–1434Google Scholar
  34. 34.
    Tsubono M, Nio Y, Shiraishi T, Morimoto H, Tseng CC, Kawabata K, Masai Y, Fukumoto M, Tobe T (1990) Increased number of suppressor T-cells and impaired IL-2 mediated T-cell function in peripheral blood of gastric cancer patients. J Clin Lab Immunol 33:107–115PubMedGoogle Scholar
  35. 35.
    Tancini G, Barni S, Rescaldani R, Fiorelli G, Vivani S, Lissoni P (1990) Analysis of T helper and suppressor lymphocytes subsets in relation to the clinical stage of solid neoplasms. Oncology 47:381–384PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Takaki Yoshikawa
    • 1
  • Hisahiko Motohashi
    • 1
  • Akira Tsuburaya
    • 1
  • Osamu Kobayashi
    • 1
  • Motonori Sairenji
    • 1
  • Yoshikazu Noguchi
    • 2
  1. 1.Third Department of SurgeryKanagawa Cancer CenterYokohamaJapan
  2. 2.First Department of SurgeryYokohama City University, School of MedicineYokohamaJapan

Personalised recommendations